Literature DB >> 20408890

Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults.

R González1, P Castro, F García, M Plana, J M Bayas, S Lafuente, B Serrano, B Mora, R Argelich, J M Gatell, A Vilella.   

Abstract

OBJECTIVES: The acquisition of adequate vaccine-induced humoral immunity is especially important in HIV-infected individuals, who are at increased risk of infections. The aim of the study was to assess the safety of administering a complete vaccination programme to successfully treated HIV-infected adults and to evaluate specific humoral responses and the effect of highly active antiretroviral therapy (HAART) interruption on these responses.
METHODS: A placebo-controlled, double-blind clinical trial was designed and 26 HIV-infected adults enrolled. Study participants were randomized to receive either a complete immunization schedule with commercial vaccines or placebo for 12 months. HAART was then discontinued for 6 months. Specific humoral responses were evaluated at baseline, at month 12 and after HAART interruption and compared between groups.
RESULTS: There were neither local nor systemic secondary effects related to vaccination. Specific humoral responses to vaccines were adequate, but a loss of immunoglobulin G titres was observed after HAART interruption in 12 study participants.
CONCLUSIONS: HAART interruption may cause impairment of previously acquired vaccine-induced immunity in HIV-infected adults.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408890     DOI: 10.1111/j.1468-1293.2010.00830.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  2 in total

Review 1.  Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection.

Authors:  Mbah P Okwen; Savanna Reid; Basile Njei; Lawrence Mbuagbaw
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09

2.  Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.

Authors:  Anne Roslev Bukh; Jesper Melchjorsen; Rasmus Offersen; Jens Magnus Bernth Jensen; Lars Toft; Henrik Støvring; Lars Ostergaard; Martin Tolstrup; Ole Schmeltz Søgaard
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.